Adding hydroxyurea to standard salvage therapy for relapsed or refractory AML
This trial tests whether adding hydroxyurea to a common combination of chemotherapy drugs can help adults with acute myeloid leukemia (AML) that has come back or not gone away. The goal is to improve the chances of remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, but younger than 75 years.
- You have AML that did not go away after initial treatment or has returned, including if there are only a few remaining leukemia cells (measurable residual disease).
- You are physically able to receive intensive chemotherapy, as determined by your doctor.
- Your kidney and liver function are within acceptable limits.
- You do not have acute promyelocytic leukemia (APL), a specific subtype of AML.
- You are willing to use effective birth control during the study and for 6 months after the last dose if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs (hydroxyurea and valproic acid, or 6-mercaptopurine and valproic acid) for people with AML or high-risk MDS who are too frail for standard chemotherapy. The goal is to see if this gentler treatment can help control the disease.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial studies HYML-122 together with cytarabine to treat adults with FLT3-positive acute myeloid leukemia (AML) that has come back or did not respond to prior treatment. It may help shrink the leukemia and improve blood-count recovery when standard treatments haven’t worked.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
Hear when a new R/R AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.